Literature DB >> 16075919

Graves' ophthalmopathy: search for shared autoantigen(s) continues.

L Bartalena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16075919     DOI： 10.1007/bf03347216

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  16 in total

1.  Smoking and Graves' disease.

Authors:  Luigi Bartalena
Journal:  J Endocrinol Invest       Date:  2002-05       Impact factor: 4.256

Review 2.  New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

Authors:  R A Ajjan; A P Weetman
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 3.  Relationship between cigarette smoking and Graves' ophthalmopathy.

Authors:  L Hegediüs; T H Brix; P Vestergaard
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 4.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

5.  Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

6.  Poorly specific binding of thyroglobulin to orbital fibroblasts from patients with Graves' ophthalmopathy.

Authors:  S Lisi; R Botta; P Agretti; S Sellari-Franceschini; C Marcocci; A Pinchera; M Marinò
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

7.  Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.

Authors:  M N Gerding; J W van der Meer; M Broenink; O Bakker; W M Wiersinga; M F Prummel
Journal:  Clin Endocrinol (Oxf)       Date:  2000-03       Impact factor: 3.478

Review 8.  Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?

Authors:  T Mizokami; M Salvi; J R Wall
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 9.  Effects of Graves' ophthalmopathy on quality of life.

Authors:  W M Wiersinga; M F Prummel; C B Terwee
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 10.  Graves' ophthalmopathy: state of the art and perspectives.

Authors:  L Bartalena; W M Wiersinga; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256
View more
  2 in total

Review 1.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 2.  Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Authors:  L Bartalena; C Marcocci; A Lai; M L Tanda
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.